Blue Water Biotech shores up portfolio with purchase of six FDA-approved treatments
Pharmaceutical Technology
JUNE 14, 2023
All six treatments are US Food and Drug Administration (FDA) approved. Blue Water bought the FDA-approved benign prostatic hyperplasia treatment from Veru for a total cost of $100m in April 2023. “We Blue Water Biotech has expanded its commercial portfolio with the purchase agreement of six assets from WraSer.
Let's personalize your content